<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acetaminophen (paracetamol) and phenylephrine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acetaminophen (paracetamol) and phenylephrine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Acetaminophen (paracetamol) and phenylephrine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9232" href="/d/html/9232.html" rel="external">see "Acetaminophen (paracetamol) and phenylephrine: Drug information"</a> and <a class="drug drug_patient" data-topicid="10944" href="/d/html/10944.html" rel="external">see "Acetaminophen (paracetamol) and phenylephrine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F5635727"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cetafen Cold [OTC];</li>
<li>Contac Cold + Flu Maximum Strength Non-Drowsy [OTC];</li>
<li>GoodSense Pressure/Pain [OTC];</li>
<li>Mapap Sinus PE [OTC];</li>
<li>Robitussin Peak Cold Nasal Relief [OTC];</li>
<li>Sinus Pain &amp; Pressure [OTC];</li>
<li>Tylenol Sinus + Headache [OTC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F55707800"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Analgesic, Nonopioid</span>;</li>
<li>
<span class="list-set-name">Decongestant</span></li></ul></div>
<div class="block dop drugH1Div" id="F5635753"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="17aa719f-0b7b-404a-908d-df382b2645db">Allergies/common cold/hay fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergies/common cold/hay fever:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> OTC dosing recommendations may vary by product and/or manufacturer. When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose. Multiple formulations of tablet strengths exist; pay close attention to the strength when ordering or administering.</p>
<p style="text-indent:-2em;margin-left:4em;">Acetaminophen 325 mg/phenylephrine 5 mg per tablet (eg, Tylenol Sinus + Headache, Sudafed PE Pressure + Pain): Children ≥12 years and Adolescents: Oral: 2 tablets every 4 hours as needed; maximum daily dose range: 10 to 12 tablets/<b>24 hours</b>; maximum daily dose varies by product; see product-specific labeling for details.</p>
<p style="text-indent:-2em;margin-left:4em;">Acetaminophen 500 mg/phenylephrine 5 mg per tablet (eg, Contact Cold &amp; Flu Day, Cetafen Cold &amp; Sinus Relief): Children ≥12 years and Adolescents: Oral: 2 tablets every 4 to 6 hours as needed; maximum daily dose: 8 tablets/<b>24 hours</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51062737"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51062738"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Limited, low-dose therapy is usually well tolerated in hepatic disease/cirrhosis; however, cases of hepatotoxicity at recommended daily acetaminophen dosages have been reported. Avoid chronic use in hepatic impairment. Also see Acetaminophen monograph.</p></div>
<div class="block doa drugH1Div" id="F5635754"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9232" href="/d/html/9232.html" rel="external">see "Acetaminophen (paracetamol) and phenylephrine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="17aa719f-0b7b-404a-908d-df382b2645db">Allergies/common cold/hay fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergies/common cold/hay fever:</b>
<b>Oral:</b>
<b>Note:</b> OTC dosing recommendations may vary by product and/or manufacturer. When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose. No dose adjustment required when converting between different acetaminophen formulations.</p>
<p style="text-indent:-2em;margin-left:4em;">Acetaminophen 325 mg/phenylephrine 5 mg: Acetaminophen 650 mg/phenylephrine 10 mg every 4 to 6 hours as needed. Refer to product-specific labeling for maximum daily dosage (maximum dosage range: acetaminophen 2.6 to 3.25 g/phenylephrine 40 to 50 mg per 24 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Acetaminophen 500 mg/phenylephrine 5 mg: Acetaminophen 1 g/phenylephrine 10 mg every 4 to 6 hours as needed; maximum: acetaminophen 4 g/phenylephrine 40 mg per 24 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990081"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50987322"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Limited, low-dose therapy is usually well tolerated in hepatic disease/cirrhosis; however, cases of hepatotoxicity at daily acetaminophen dosages &lt;4 g/day have been reported. Avoid chronic use in hepatic impairment. Also see Acetaminophen monograph.</p></div>
<div class="block adr drugH1Div" id="F5635737"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="block coi drugH1Div" id="F5635733"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication, do not use with any other drug containing acetaminophen; in combination with or within 14 days of stopping a monoamine oxidase inhibitor (MAOI); if you are hypersensitive to acetaminophen, phenylephrine, or any component of the formulation; longer than 10 days (for pain), 3 days (for fever), or 2 days (sore throat).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F5635734"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Acetaminophen has been associated with acute liver failure, at times resulting in liver transplant and death. Hepatotoxicity is usually associated with excessive acetaminophen intake and often involves more than one product that contains acetaminophen. Do not exceed the maximum recommended daily dose (&gt;4 g daily in adults). In addition, long-term daily dosing may also result in liver damage in some patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin reactions: Serious and potentially fatal skin reactions, including acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), have occurred rarely with acetaminophen use. Discontinue therapy at the first appearance of skin rash.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity/anaphylactic reactions: Hypersensitivity and anaphylactic reactions have been reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ethanol use: Use with caution in patients with alcoholic liver disease; consuming ≥3 alcoholic drinks/day may increase the risk of liver damage. Avoid ethanol or limit to &lt;3 alcoholic drinks/day.</p>
<p style="text-indent:-2em;margin-left:4em;">• G6PD deficiency: Use with caution in patients with known G6PD deficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment or active liver disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; more likely to experience adverse reactions to sympathomimetics.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dosage limit: Limit acetaminophen dose from all sources &lt;4 g/day (adults).</p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): When used for self-medication (OTC), discontinue use and notify health care provider if pain or nasal congestion does not improve or gets worse within 7 days or are accompanied by fever; fever gets worse or lasts &gt;3 days; if any new symptoms or nervousness, dizziness, or sleeplessness occur; or if redness or swelling is present. If sore throat persists for &gt;2 days, is accompanied or followed by a fever, headache, rash, nausea, or vomiting, contact health care provider.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F55707804"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Hepatoxicity has been reported in patients using acetaminophen. In pediatric patients, this is most commonly associated with supratherapeutic dosing, more frequent administration than recommended, and use of multiple acetaminophen-containing products; however, hepatotoxicity has been rarely reported with recommended dosages (AAP [Sullivan 2011]; Heard 2014). All sources of acetaminophen (eg, prescription, OTC, combination) should be considered when evaluating a patient's maximum daily dose. To lower the risk for hepatotoxicity, the maximum daily acetaminophen dose should be limited to ≤75 mg/kg/day (maximum of 5 daily doses), not to exceed 4,000 mg/day (AAP [Sullivan 2011]; Heard 2014; Krenzelok 2012; Lavonas 2010). Acetaminophen avoidance or a lower total daily dose (2,000 to 3,000 mg/day) has been suggested for adults with increased risk for acetaminophen hepatotoxicity (eg, malnutrition, certain liver diseases, use of drugs that interact with acetaminophen metabolism); similar data are unavailable in pediatric patients (Hayward 2016; Larson 2007; Worriax 2007).</p>
<p style="text-indent:0em;margin-top:2em;">Safety and efficacy for the use of cough and cold products in pediatric patients &lt;4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in young children. Serious adverse effects including death have been reported (in some cases, high blood concentrations of pseudoephedrine were found). Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. The FDA does not recommend OTC uses for these products in pediatric patients &lt;2 years of age and recommends to use with caution in pediatric patients ≥2 years of age. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient (AAP 2018; CDC 2007; FDA 2017; FDA 2018). Multiple formulations of tablet strengths exist; pay close attention to the strength when ordering or administering.</p></div>
<div class="block foc drugH1Div" id="F5635759"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product.</p>
<p style="text-indent:-2em;margin-left:2em;">Caplet, oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Contac Cold + Flu Maximum Strength Non Drowsy: Acetaminophen 500 mg and phenylephrine hydrochloride 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Mapap Sinus PE, Sudafed PE Pressure + Pain: Acetaminophen 325 mg and phenylephrine hydrochloride 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Tylenol Sinus + Headache: Acetaminophen 325 mg and phenylephrine hydrochloride 5 mg</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Cetafen Cold: Acetaminophen 500 mg and phenylephrine hydrochloride 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;">GoodSense Pressure/Pain PE: Acetaminophen 325 mg and phenylephrine hydrochloride 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Robitussin Peak Cold Nasal Relief: Acetaminophen 325 mg and phenylephrine hydrochloride 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Sinus Pain &amp; Pressure: Acetaminophen 500 mg and phenylephrine hydrochloride 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Acetaminophen 325 mg and phenylephrine hydrochloride 5 mg</p></div>
<div class="block geq drugH1Div" id="F5635729"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes: Caplet, tablet</p></div>
<div class="block fee drugH1Div" id="F16321810"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Panadol Cold/Flu Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5-325 mg (per each): $0.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sudafed PE Sinus Pressure+Pain Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5-325 mg (per each): $0.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Tylenol Sinus+Headache Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5-325 mg (per each): $0.30</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52616639"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Swallow caplets whole; do not crush, chew, or dissolve.</p></div>
<div class="block adm drugH1Div" id="F5635757"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Swallow caplets, gelcaps, and liquid-filled capsules whole; do not crush, chew, or dissolve.</p></div>
<div class="block sts drugH1Div" id="F28651478"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at room temperature. Avoid heat and humidity. </p></div>
<div class="block usep drugH1Div" id="F55707803"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Temporary relief of symptoms (eg, nasal congestion, sinus congestion/pressure, minor aches and pain, headache, fever, sore throat) associated with hay fever, other respiratory allergies, and the common cold (OTC product: FDA approved in ages ≥12 years and adults).</p></div>
<div class="block mst drugH1Div" id="F5635724"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Duplicate therapy issues: This product contains acetaminophen, which may be a component of combination products. Do not exceed the maximum recommended daily dose of acetaminophen.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F5635744"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F5635743"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May increase the serum concentration of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the hepatotoxic effect of Acetaminophen.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atropine (Systemic): May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider delaying skin testing until alpha1-agonists are no longer required, or use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the hypertensive effect of Alpha1-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Busulfan: Acetaminophen may increase the serum concentration of Busulfan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroprocaine (Systemic): May enhance the hypotensive effect of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: May diminish the therapeutic effect of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.  Management: Avoid coadministration of acetaminophen and dasatinib if possible. If coadministration is unavoidable, monitor for signs/symptoms of hepatotoxicity, particularly in patients with greater acetaminophen exposure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May enhance the vasoconstricting effect of Alpha1-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: Decongestants may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flucloxacillin: May enhance the adverse/toxic effect of Acetaminophen. Specifically, the risk for high anion gap metabolic acidosis may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May decrease the serum concentration of Acetaminophen. Specifically, serum concentrations of acetaminophen may be decreased (leading to decreased efficacy), but the formation of the toxic N-acetyl-p-benzoquinone imine (NAPQI) metabolite may be increased (leading to increased hepatotoxicity).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Do not use hyaluronidase to enhance the dispersion or absorption of phenylephrine. Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Acetaminophen may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Alpha1-Agonists may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: May enhance the hepatotoxic effect of Acetaminophen. Isoniazid may increase the metabolism of Acetaminophen. Specifically, formation of the hepatotoxic NAPQI metabolite may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: Acetaminophen may decrease the serum concentration of LamoTRIgine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorlatinib: May decrease the serum concentration of Acetaminophen.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: May decrease the serum concentration of UGT1A1 Substrates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pergolide: May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May increase the metabolism of Acetaminophen. Specifically, formation of the hepatotoxic NAPQI metabolite may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenylephrine (Systemic): Acetaminophen may increase the serum concentration of Phenylephrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May increase the metabolism of Acetaminophen. Specifically, formation of the hepatotoxic NAPQI metabolite may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite. Management: Consider limiting acetaminophen use in combination with probenecid. Probenecid may reduce clearance of acetaminophen to one of its non-toxic metabolities, increasing the risk for acetaminophen toxicity, even a lower doses.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May increase the serum concentration of Phenylephrine (Systemic). Management: Monitor patients closely for increased side effects of phenylephrine if propacetamol is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May enhance the hepatotoxic effect of Acetaminophen. RifAMPin may decrease the serum concentration of Acetaminophen.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.  Management: Avoid coadministration of acetaminophen and sorafenib if possible. If coadministration is unavoidable, monitor for signs/symptoms of hepatotoxicity, particularly in patients with greater acetaminophen exposure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the therapeutic effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the therapeutic effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines: Acetaminophen may diminish the therapeutic effect of Vaccines.  Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. This appears most likely with daily acetaminophen doses exceeding 1.3 or 2 g/day for multiple consecutive days. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F5635756"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine and/or sodium.</p></div>
<div class="block pri drugH1Div" id="F54814452"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Refer to individual monographs.</p></div>
<div class="block pha drugH1Div" id="F5635748"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: Although not fully elucidated, the analgesic effects are believed to be due to activation of descending serotonergic inhibitory pathways in the CNS. Interactions with other nociceptive systems may be involved as well (Smith 2009). Antipyresis is produced from inhibition of the hypothalamic heat-regulating center.</p>
<p style="text-indent:-2em;margin-left:2em;">Phenylephrine: Causes vasoconstriction of the arterioles of the nasal mucosa.</p></div>
<div class="block phk drugH1Div" id="F5635750"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F46681762"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Desenfriol descongestivo | Dristan descongestivo | Duflegrip free | Gripaben descongestivo | Itedal plus | Kroltonex</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Aft pharmaceuticals cold &amp; flu relief | AMCAL SINUS PAIN RELIEF PE | Chemists Own Sinus Pain Relief PE | Chemists' own cold &amp; flu relief pe | Chemists' own day + night cold &amp; flu relief pe | Chemists' own sinus pain relief pe | Cip cold &amp; flu day and night tablets | Cipla sinus pain relief pe day | Codral cold &amp; flu | Codral day &amp; night | Codral relief cold &amp; flu + decongestant | Cold &amp; Flu Relief PE | Coles cold &amp; flu pain relief + pe decongestant | Demazin cold + flu relief day + night | Demazin pe multi action cold &amp; flu relief | Demazin pe multi action cold&amp;flu relief | Dimetapp pe sinus pain | Easeacold paracetamol &amp; phenylephrine cold, flu + decongestant | Hedanol cold &amp; flu decongestant with pain relief | Help@hand for cold &amp; flu relief | Maxiclear cold &amp; flu relief | Maxiclear cold &amp; flu relief sinus &amp; pain relief | Maxiclear Sinus &amp; Pain Relief | Medi cold cold, flu + decongestant | Medichoice cold &amp; flu + pain relief pe | Medix cold &amp; flu + pain relief pe | Medix nasal decongestant + pain relief pe | Medix sinus + pain relief pe | Nyal cold and flu | Nyal sinus + pain relief pe | Panadol cold &amp; flu plus decongestant | Panadol sinus pain &amp; congestion relief | Panadol sinus pain &amp; congestion relief day &amp; night | Paraphen | Pharmacy action cold &amp; flu pe | Pharmacy care sinus pain relief pe | Pharmacy choice cold &amp; flu + sinus pe | Pharmacy choice sinus pain relief pe | Pharmacy health cold &amp; flu relief pe | Priceline cold &amp; flu relief pe | Priceline sinus pe | Robitussin cold &amp; flu + decongestant | Robitussin head cold &amp; sinus | Sinus pain relief PE | Soul pattinson cold &amp; flu relief pe | Sudafed pe sinus + pain relief | Terrywhite chemmart cold &amp; flu relief pe | Trust sinus pain relief pe | Vicks ActionCold &amp; Flu Day Relief | Vidalife cold &amp; flu pe | Your Pharmacy Head Cold Relief | Your pharmacy sinus pain relief</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Benegrip multi dia | Corizz Dia | Fluviral dia | Gripen dia | Naldecon dia | Naldecon multi | Neolefrin dia</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Pax dia | Refritab | Sinutab plus ns</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Doregrippin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Coltalin-Nd</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Bodrex flu</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Flusiquim | Tempra xt dia | Theraflu td</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Panadol cold flu nd</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Codral cold &amp; flu | Pharmacy health Cold &amp; Flu Day + Night PE</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Vitapyrena plus</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Analem | Nasatapp no drowse</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Gripex duo</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Acetaminophen congestion and pain | Panadol cold &amp; flu nondrowsy | Sinutab sinus</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Antigrippine trieffect</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Lemsip Cold and Flu with Decongestant | Panadol Cold and Flu Vapour Release plus Decongestant | Panadol Sinus Relief PE | Panda Zokam</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Decolgen Non Drowse | Panadol Sinus Max</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Hapacol cs day</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Dristan cold nd</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). Cough and cold medicines should not be prescribed, recommended or used for respiratory illnesses in young children. Updated June 12, 2018. Available at http://www.choosingwisely.org/clinician-lists/american-academy-pediatrics-cough-and-cold-medicines-for-children-under-four/
                  </div>
</li>
<li>
<div class="reference">
                  Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10332548">
<a name="10332548"></a>Bagheri H, Bernhard NB, Montastruc JL. Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen. <i>Ann Pharmacother</i>. 1999;33(4):506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/10332548/pubmed" id="10332548" target="_blank">10332548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25456003">
<a name="25456003"></a>Caldeira D, Costa J, Barra M, Pinto FJ, Ferreira JJ. How safe is acetaminophen use in patients treated with vitamin K antagonists? A systematic review and meta-analysis. <i>Thromb Res.</i> 2015; 135(1):58-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/25456003/pubmed" id="25456003" target="_blank">25456003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17218934">
<a name="17218934"></a>Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. <i>MMWR Morb Mortal Wkly Rep</i>. 2007;56(1):1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/17218934/pubmed" id="17218934" target="_blank">17218934</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cetafen Cold (acetaminophen/phenylephrine) [prescribing information]. Seattle, WA: Hart Health; received April 2015.</div>
</li>
<li>
<div class="reference">
                  Contac Cold + Flu Day Non-Drowsy Maximum Strength (acetaminophen/phenylephrine) [prescribing information]. Morgantown, WV: Mylan Consumer Healthcare Inc; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA). Most young children with a cough or cold don't need medicines. July 18, 2017. Available at <a href="https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm" target="_blank">https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm</a>. Last accessed November 2, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>Food and Drug Administration (FDA). Use caution when giving cough and cold products to kids. Updated February 8, 2018. Available at <a href="https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm" target="_blank">https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm</a>. Last accessed November 2, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12871405">
<a name="12871405"></a>Gadisseur AP, Van Der Meer FJ, Rosendaal FR. Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial. <i>J Thromb Haemost</i>. 2003;1(4):714-717.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/12871405/pubmed" id="12871405" target="_blank">12871405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12523469">
<a name="12523469"></a>Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al. Warfarin and Acetaminophen Interaction. <i>Pharmacotherapy</i>. 2003;23(1):109-112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/12523469/pubmed" id="12523469" target="_blank">12523469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26460177">
<a name="26460177"></a>Hayward KL, Powell EE, Irvine KM, Martin JH. Can paracetamol (acetaminophen) be administered to patients with liver impairment? <i>Br J Clin Pharmacol</i>. 2016;81(2):210-222. doi: 10.1111/bcp.12802<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/26460177/pubmed" id="26460177" target="_blank">26460177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22407198">
<a name="22407198"></a>Heard K, Bui A, Mlynarchek SL, et al. Toxicity from repeated doses of acetaminophen in children: assessment of causality and dose in reported cases. <i>Am J Ther</i>. 2014;21(3):174-183.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/22407198/pubmed" id="22407198" target="_blank">22407198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9496982">
<a name="9496982"></a>Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation. <i>JAMA</i>. 1998;279(9):657-662.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/9496982/pubmed" id="9496982" target="_blank">9496982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22530736">
<a name="22530736"></a>Krenzelok EP, Royal MA. Confusion: acetaminophen dosing changes based on NO evidence in adults. <i>Drugs R D</i>. 2012;12(2):45-48. doi: 10.2165/11633010-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/22530736/pubmed" id="22530736" target="_blank">22530736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9987702">
<a name="9987702"></a>Kwan D, Bartle WR, Walker SE. The Effects of Acetaminophen on Pharmacokinetics and Pharmacodynamics of Warfarin. <i>J Clin Pharmacol</i>. 1999;39(1):68-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/9987702/pubmed" id="9987702" target="_blank">9987702</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kwan D, Bartle WR, Walker SE. The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin. <i>Clin Pharmacol Ther</i>. 1995;57:212.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17723918">
<a name="17723918"></a>Larson AM. Acetaminophen hepatotoxicity. <i>Clin Liver Dis</i>. 2007;11(3):525-548. doi: 10.1016/j.cld.2007.06.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/17723918/pubmed" id="17723918" target="_blank">17723918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21098156">
<a name="21098156"></a>Lavonas EJ, Reynolds KM, Dart RC. Therapeutic acetaminophen is not associated with liver injury in children: a systematic review. <i>Pediatrics</i>. 2010;126(6):e1430-e1444.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/21098156/pubmed" id="21098156" target="_blank">21098156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7565951">
<a name="7565951"></a>Lee WM. Drug-Induced Hepatotoxicity. <i>N Engl J Med</i>. 1995;333(17):1118-1127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/7565951/pubmed" id="7565951" target="_blank">7565951</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mapap Sinus Congestion and Pain (acetaminophen/phenylephrine) [prescribing information]. Livonia, MI: Major Pharmaceuticals; August 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10980926">
<a name="10980926"></a>McClain CJ, Price S, Barve S, et al. Acetaminophen Hepatotoxicity: An Update. <i>Curr Gastroenterol Rep</i>. 1999;1(1):42-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/10980926/pubmed" id="10980926" target="_blank">10980926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20685496">
<a name="20685496"></a>Mehlisch DR, Aspley S, Daniels SE, et al. Comparison of the Analgesic Efficacy of Concurrent Ibuprofen and Paracetamol With Ibuprofen or Paracetamol Alone in the Management of Moderate to Severe Acute Postoperative Dental Pain in Adolescents and Adults: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Dose, Two-Center, Modified Factorial Study. <i>Clin Ther</i>. 2010;32(5):882-895.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/20685496/pubmed" id="20685496" target="_blank">20685496</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Panadol (acetaminophen/phenylephrine) [prescribing information]. Warren, NJ: GSK Consumer Healthcare; received April 2020.</div>
</li>
<li>
<div class="reference">
                  QlearQuil Daytime Sinus and Congestion (acetaminophen/phenylephrine) [prescribing information]. Cincinnati, OH: Procter &amp; Gamble; no date.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10512064">
<a name="10512064"></a>Shek KL, Chan LN, Nutescu E. Warfarin-Acetaminophen Drug Interaction Revisited. <i>Pharmacotherapy</i>. 1999;19(10):1153-1158.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/10512064/pubmed" id="10512064" target="_blank">10512064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19165309">
<a name="19165309"></a>Smith HS. Potential analgesic mechanisms of acetaminophen. <i>Pain Physician</i>. 2009;12(1):269-280.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/19165309/pubmed" id="19165309" target="_blank">19165309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21357332">
<a name="21357332"></a>Sullivan JE, Farrar HC. Fever and antipyretic use in children. <i>Pediatrics</i>. 2011;127(3):580-587.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/21357332/pubmed" id="21357332" target="_blank">21357332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11123483">
<a name="11123483"></a>Tanaka E, Yamazaki K, Misawa S. Update: The Clinical Importance of Acetaminophen Hepatotoxicity in Nonalcoholic and Alcoholic Subjects. <i>J Clin Pharm Ther</i>. 2000;25(5):325-332.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/11123483/pubmed" id="11123483" target="_blank">11123483</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Tylenol Sinus + Headache (acetaminophen/phenylephrine) [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare; received February 2021.</div>
</li>
<li>
<div class="reference">
                  Tylenol Sinus Plus Headache Day (acetaminophen/phenylephrine) [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12426965">
<a name="12426965"></a>van den Bemt PM, Geven LM, Kuitert NA, et al. The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice. <i>Pharm World Sci</i>. 2002;24(5):201-204.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/12426965/pubmed" id="12426965" target="_blank">12426965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17669296">
<a name="17669296"></a>Worriax JD, Yates JE, Flake D, Saseen JJ. Clinical inquiries. Alcoholic liver disease: is acetaminophen safe?. <i>J Fam Pract</i>. 2007;56(8):673-674.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-pediatric-drug-information/abstract-text/17669296/pubmed" id="17669296" target="_blank">17669296</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 131431 Version 33.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
